Crizotinib-induced fatal fulminant liver failure-Reference-Cited by-同舟云学术

Crizotinib-induced fatal fulminant liver failure

Published:2016-03 Issue: Volume:93 Page:17-19
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

van Geel Robin M.J.M.^ORCID,Hendrikx Jeroen J.M.A.,Vahl Jelmer E.,van Leerdam Monique E.,van den Broek Daan,Huitema Alwin D.R.,Beijnen Jos H.,Schellens Jan H.M.,Burgers Sjaak A.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference11 articles.

1. Global estimates of cancer prevalence for 27 sites in the adult population in 2008;Bray;Int. J. Cancer,2013

2. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

3. Treating ALK-positive lung cancer—early successes and future challenges;Camidge;Nat. Rev. Clin. Oncol.,2012

4. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N. Engl. J. Med.,2013

5. FDA, Prescribing information Xalkori® (crizotinib), (2013).

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The involvement of the Stat1/Nrf2 pathway in exacerbating Crizotinib-induced liver injury: implications for ferroptosis;Cell Death & Disease;2024-08-19

2. Crizotinib inhibits the metabolism of tramadol by non-competitive suppressing the activities of CYP2D1 and CYP3A2;PeerJ;2024-05-30

3. Drug-Induced Liver Injury Associated with Alk Inhibitors: A Pharmacovigilance Analysis of the Fda Adverse Event Reporting System (Faers);2024

4. A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma;Cancers;2022-03-19

5. An Insight on the Pathways Involved in Crizotinib and Sunitinib Induced Hepatotoxicity in HepG2 Cells and Animal Model;Frontiers in Oncology;2022-01-28